Seres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.com
Seres Therapeutics (NASDAQ:MCRB – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday. Other analysts have also issued research reports about the stock. Chardan Capital restated a “buy” rating and set a $25.00 price target on shares of Seres Therapeutics […]
Seres Therapeutics (NASDAQ:MCRB – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday. Other analysts have also issued research reports about the stock. Chardan Capital restated a “buy” rating and set a $25.00 price target on shares of Seres Therapeutics […]